Leaders in oncology share why the American Society of Clinical Oncology (ASCO) meeting remains a top global gathering for breakthroughs, networking, and lifelong learning.
Danny Rischin, MD
Advertisement
Medical oncologist, clinician researcher, Peter McCallum Cancer Centre.
Articles by Danny Rischin, MD
Danny Rischin, MD, medical oncologist, clinician researcher, Peter McCallum Cancer Centre, discusses a novel adjuvant treatment approach for patients with locally advanced cutaneous squamous cell carcinoma (CSCC).
Cemiplimab significantly enhances disease-free survival in high-risk cSCC patients, reducing recurrence and metastasis risks, according to findings presented at ASCO.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Hans Lee, MD, Discusses “Off-the-Shelf” Solution for Rare Blood Disorder With No Approved Therapies
2
ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity
3
CMS Proposes Permanent Rules for Medicare Drug Price Negotiation
4
AI Billing, GLP-1s Among Forces Driving 9% Health Cost Spike
5